LENT Prognostic Score Malignant Pleural Effusion

The LENT score predicts survival in malignant pleural effusion using LDH, ECOG performance status, neutrophil‑to‑lymphocyte ratio, and tumor type 1 [Level I evidence].

Plasma fluid LDH, U/L
< 15000≥ 1500+1
ECOG Score
0 (asymptomatic)01 (symptomatic but ambulatory)+12 (symptomatic, in bed < 50% of day)+23-4 (symptomatic, in bed > 50% of day or bedbound)+3
Serum neutrophil-to-lymphocyte ratio (from CBC)
< 90≥ 9+1
Tumor type
Mesothelioma or hematologic malignancy0Breast or gynecologic cancer or RCC+1Lung or any other cancer+2

使用適応

Used in adults with confirmed malignant pleural effusion to estimate short‑term survival and guide discussions on goals of care and intensity of pleural interventions. Identifies low-, moderate-, and high‑risk groups using pleural LDH, ECOG status, neutrophil‑to‑lymphocyte ratio, and tumor type, validated to outperform ECOG alone for survival prediction 1 [Level I evidence]. Enables tailoring of pleurodesis vs indwelling catheter strategies and early palliative planning.

洞察と注意事項

Stratifies MPE survival using LDH, ECOG, NLR, and tumor type, giving clearer 1–6‑month mortality prediction than ECOG alone (median survivals 319, 130, 44 days) 1 [Level II evidence]. Use cautiously: it underestimates survival in EGFR‑mutant lung adenocarcinoma 2 [Level II evidence] and misclassifies sarcomatoid mesothelioma as low‑risk despite poor outcomes 3 [Level II evidence]. Not validated to guide treatment decisions (BTS 2023) 4 [Level II evidence].